General Gynecology Gynecologic Oncology

Chapter 34: Cancer: NaProTECHNOLOGY and Early Detection

Hilgers TW

The Medical and Surgical Practice of NaProTECHNOLOGY, 413-424, 2004

RRM Academy Synopsis

Cycle charting may help flag endometrial and breast cancer risk

Creighton Model charting may help identify women at higher risk of endometrial and breast cancer, a 2004 textbook chapter on NaProTECHNOLOGY reports. The chapter draws on case presentations of endometrial and ovarian cancer and a study of 28 women with breast cancer.

Key Findings

  • Three case presentations describe women whose Creighton Model charts recorded abnormal bleeding before a diagnosis of uterine cancer. Each is reported with no signs of recurrence five to seven years later.
  • The chapter states that chronic absence of ovulation with unopposed estrogen appears to be the major underlying factor in endometrial cancer, and that charting identifies women with irregular or unusual bleeding.
  • In the breast cancer study, 28 women who charted later developed the disease. Subgroups with data differed significantly from controls: lower post-Peak progesterone, lower mucus cycle scores, more variable post-Peak phase length.
  • A cited 1981 study of two groups of infertile women reported a 5.4 times increased incidence of premenopausal breast cancer in the group with progesterone deficiency.
  • Two ovarian cancer case presentations describe a late luteal defect with premenstrual bleeding in one woman and a large follicle before rupture in the other. The chapter calls for further research.

RRM Context

Restorative reproductive medicine (RRM) regards the ovulatory cycle as a source of information about a woman's health and looks for the cause of a problem before choosing a treatment. NaProTECHNOLOGY, developed by Dr. Thomas W. Hilgers, applies that principle through Creighton Model charting, which records bleeding, mucus and cycle length as the woman's own biomarkers. The chapter challenges the proposal that normal ovulation is itself a precursor to ovarian cancer, an idea it ties to the rationale for ongoing contraceptive use. Charting ties each evaluation to the body's own signals.

Abstract

This chapter discusses endometrial, breast and ovarian cancer and the potential of NaProTECHNOLOGY to aid early detection and the identification of women at high risk. For endometrial cancer, the chapter describes how CrMS charting can detect abnormal bleeding in its earliest stages and presents three case reports of uterine cancer in women who charted their cycles. In 28 women who were charting their cycles and later developed breast cancer, Hilgers reports lower post-Peak progesterone levels, lower mucus cycle scores and greater variability in the length of the post-Peak phase than in controls, and calls for further research. For ovarian cancer, the chapter presents two case reports, states that the CrMS and NaProTECHNOLOGY have only minimal research to offer, and rejects the suggestion that normal ovulation and menstrual cycles are by themselves a precursor to the disease.

Topics

By this author

Related research

General Gynecology › Gynecologic Oncology › Endometrial Cancer · Diagnostics › Cycle Biomarkers › Temperature Tracking · Fertility Awareness › Biomarkers › Basal Body Temperature
Thomas W Hilgers
Tom Hilgers, T Hilgers
Hilgers et al. 2004, Hilgers 2004